FDA Approves Italfarmaco's Duvyzat for All Genetic Variants of Duchenne MD

The U.S. Food and Drug Administration (FDA) has approved the first oral nonsteroidal medication, Duvyzat (givinostat), developed by the privately held Italfarmaco Group, for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older with all genetic variants of DMD. This approval marks a significant advancement in the treatment options available for individuals suffering from this inherited muscle-wasting disorder, characterized by progressive muscle degeneration and weakness.